Compared with IDH-1 wild-type (IDH-1(-)), the glioma patients with IDH-1 mutant-type (IDH-1(+)) have longer survival time and better efficacy of chemoradiotherapy [3]. The gene discussed is IDH1; the disease is central nervous system cancer.